Medac Will Market Fresenius Kabi’s Adalimumab In Germany
Collaboration On Idacio Will Begin From The Start Of June
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
You may also be interested in...
Fresenius Kabi discussed the latest around the potential of an FDA warning letter at its key injectables plant in Melrose Park, after earlier this year confirming that no product launches from the site were anticipated in 2021.
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Fresenius Kabi is looking to make headway into biosimilars but saw its progress limited by COVID-19 in Q2. Management gave an update on the company’s endeavors during the Q2 earnings call, including key tender victories.